THP-1 Monocytic Cells Are Polarized to More Antitumorigenic Macrophages by Serial Treatment with Phorbol-12-Myristate-13-Acetate and PD98059
Abstract
:1. Introduction
2. Materials and Methods
2.1. Materials
2.2. Cell Culture
2.3. THP-1 Differentiation and Polarization Analysis by Flow Cytometry
2.4. RNA Extraction and Reverse Transcription (RT) and PCR
2.5. Immunoblotting
2.6. Cell Morphology by Microscopy
2.7. Migration Assay
2.8. Phagocytosis Assay
2.9. Statistical Analysis
3. Results
3.1. PD98059 Influences the Differentiation and Polarization of THP-1 Cells in Response to PMA
3.2. PD98059 Affects the Expression Levels of Genes Related to Macrophage Differentiation and Polarization
3.3. PD98059 Increases the Motility of Differentiated THP-1 Cells
3.4. PD98059 Promotes Phagocytosis by Differentiated THP-1 Cells
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ho, W.J.; Jaffee, E.M.; Zheng, L. The tumour microenvironment in pancreatic cancer—Clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 2020, 17, 527–540. [Google Scholar] [CrossRef]
- Mantovani, A.; Allavena, P.; Marchesi, F.; Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 2022, 21, 799–820. [Google Scholar] [CrossRef] [PubMed]
- Cassetta, L.; Pollard, J.W. A timeline of tumour-associated macrophage biology. Nat. Rev. Cancer 2023, 23, 238–257. [Google Scholar] [CrossRef]
- Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549–555. [Google Scholar] [CrossRef]
- Caronni, N.; La Terza, F.; Vittoria, F.M.; Barbiera, G.; Mezzanzanica, L.; Cuzzola, V.; Barresi, S.; Pellegatta, M.; Canevazzi, P.; Dunsmore, G.; et al. IL-1beta(+) macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 2023, 623, 415–422. [Google Scholar] [CrossRef] [PubMed]
- Gordon, S.R.; Maute, R.L.; Dulken, B.W.; Hutter, G.; George, B.M.; McCracken, M.N.; Gupta, R.; Tsai, J.M.; Sinha, R.; Corey, D.; et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017, 545, 495–499. [Google Scholar] [CrossRef] [PubMed]
- Hirayama, D.; Iida, T.; Nakase, H. The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis. Int. J. Mol. Sci. 2017, 19, 92. [Google Scholar] [CrossRef]
- Malesci, A.; Bianchi, P.; Celesti, G.; Basso, G.; Marchesi, F.; Grizzi, F.; Di Caro, G.; Cavalleri, T.; Rimassa, L.; Palmqvist, R.; et al. Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncoimmunology 2017, 6, e1342918. [Google Scholar] [CrossRef]
- Duan, Z.; Luo, Y. Targeting macrophages in cancer immunotherapy. Signal Transduct. Target. Ther. 2021, 6, 127. [Google Scholar] [CrossRef] [PubMed]
- Shields, C.W., IV; Evans, M.A.; Wang, L.L.; Baugh, N.; Iyer, S.; Wu, D.; Zhao, Z.; Pusuluri, A.; Ukidve, A.; Pan, D.C.; et al. Cellular backpacks for macrophage immunotherapy. Sci. Adv. 2020, 6, eaaz6579. [Google Scholar] [CrossRef]
- Murray, P.J.; Allen, J.E.; Biswas, S.K.; Fisher, E.A.; Gilroy, D.W.; Goerdt, S.; Gordon, S.; Hamilton, J.A.; Ivashkiv, L.B.; Lawrence, T.; et al. Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity 2014, 41, 14–20. [Google Scholar] [CrossRef] [PubMed]
- Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8, 958–969. [Google Scholar] [CrossRef]
- Italiani, P.; Boraschi, D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front. Immunol. 2014, 5, 514. [Google Scholar] [CrossRef] [PubMed]
- Baumann, D.; Drebant, J.; Hagele, T.; Burger, L.; Serger, C.; Lauenstein, C.; Dudys, P.; Erdmann, G.; Offringa, R. p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition. J. Immunother. Cancer 2021, 9, e002319. [Google Scholar] [CrossRef]
- Kashfi, K.; Kannikal, J.; Nath, N. Macrophage Reprogramming and Cancer Therapeutics: Role of iNOS-Derived NO. Cells 2021, 10, 3194. [Google Scholar] [CrossRef] [PubMed]
- Ron, D.; Kazanietz, M.G. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 1999, 13, 1658–1676. [Google Scholar] [CrossRef] [PubMed]
- You, H.J.; Lee, J.W.; Yoo, Y.J.; Kim, J.H. A pathway involving protein kinase Cdelta up-regulates cytosolic phospholipase A(2)alpha in airway epithelium. Biochem. Biophys. Res. Commun. 2004, 321, 657–664. [Google Scholar] [CrossRef] [PubMed]
- Eichmann, T.O.; Lass, A. DAG tales: The multiple faces of diacylglycerol--stereochemistry, metabolism, and signaling. Cell Mol. Life Sci. 2015, 72, 3931–3952. [Google Scholar] [CrossRef] [PubMed]
- Lund, M.E.; To, J.; O’Brien, B.A.; Donnelly, S. The choice of phorbol 12-myristate 13-acetate differentiation protocol influences the response of THP-1 macrophages to a pro-inflammatory stimulus. J. Immunol. Methods 2016, 430, 64–70. [Google Scholar] [CrossRef]
- Verma, V.; Paek, A.R.; Choi, B.K.; Hong, E.K.; You, H.J. Loss of zinc-finger protein 143 contributes to tumour progression by interleukin-8-CXCR axis in colon cancer. J. Cell Mol. Med. 2019, 23, 4043–4053. [Google Scholar] [CrossRef]
- Tsuchiya, S.; Yamabe, M.; Yamaguchi, Y.; Kobayashi, Y.; Konno, T.; Tada, K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 1980, 26, 171–176. [Google Scholar] [CrossRef] [PubMed]
- Daigneault, M.; Preston, J.A.; Marriott, H.M.; Whyte, M.K.; Dockrell, D.H. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 2010, 5, e8668. [Google Scholar] [CrossRef]
- Qin, Z. The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature. Atherosclerosis 2012, 221, 2–11. [Google Scholar] [CrossRef] [PubMed]
- Genin, M.; Clement, F.; Fattaccioli, A.; Raes, M.; Michiels, C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer 2015, 15, 577. [Google Scholar] [CrossRef] [PubMed]
- James, J.R.; Curd, J.; Ashworth, J.C.; Abuhantash, M.; Grundy, M.; Seedhouse, C.H.; Arkill, K.P.; Wright, A.J.; Merry, C.L.R.; Thompson, A. Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML. Int. J. Mol. Sci. 2023, 24, 4235. [Google Scholar] [CrossRef] [PubMed]
- Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3, 23–35. [Google Scholar] [CrossRef] [PubMed]
- Sica, A.; Mantovani, A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Investig. 2012, 122, 787–795. [Google Scholar] [CrossRef] [PubMed]
- He, L.; Jhong, J.H.; Chen, Q.; Huang, K.Y.; Strittmatter, K.; Kreuzer, J.; DeRan, M.; Wu, X.; Lee, T.Y.; Slavov, N.; et al. Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors. Cell Rep. 2021, 37, 109955. [Google Scholar] [CrossRef]
- Lee, E.Y.; Kim, Y.H.; Rayhan, M.A.; Kang, H.G.; Kim, J.H.; Park, J.W.; Park, S.Y.; Lee, S.H.; You, H.J. New established cell lines from undifferentiated pleomorphic sarcoma for in vivo study. BMB Rep. 2023, 56, 258–264. [Google Scholar] [CrossRef]
- Park, J.; Bai, B.; Ryu, D.; Liu, T.; Lee, C.; Luo, Y.; Lee, M.J.; Huang, L.; Shin, J.; Zhang, Y.; et al. Artificial intelligence-enabled quantitative phase imaging methods for life sciences. Nat. Methods 2023, 20, 1645–1660. [Google Scholar] [CrossRef]
- Lee, E.Y.; Yu, J.Y.; Paek, A.R.; Lee, S.H.; Jang, H.; Cho, S.Y.; Kim, J.H.; Kang, H.G.; Yun, T.; Oh, S.E.; et al. Targeting TJP1 attenuates cell-cell aggregation and modulates chemosensitivity against doxorubicin in leiomyosarcoma. J. Mol. Med. 2020, 98, 761–773. [Google Scholar] [CrossRef]
- Paek, A.R.; Lee, C.H.; You, H.J. A role of zinc-finger protein 143 for cancer cell migration and invasion through ZEB1 and E-cadherin in colon cancer cells. Mol. Carcinog. 2014, 53 (Suppl. S1), E161–E168. [Google Scholar] [CrossRef]
- Homicsko, K.; Zygoura, P.; Norkin, M.; Tissot, S.; Shakarishvili, N.; Popat, S.; Curioni-Fontecedro, A.; O’Brien, M.; Pope, A.; Shah, R.; et al. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma. J. Immunother. Cancer 2023, 11, e007585. [Google Scholar] [CrossRef] [PubMed]
- Ascierto, P.A.; Ferrucci, P.F.; Fisher, R.; Del Vecchio, M.; Atkinson, V.; Schmidt, H.; Schachter, J.; Queirolo, P.; Long, G.V.; Di Giacomo, A.M.; et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med. 2019, 25, 941–946. [Google Scholar] [CrossRef]
- Gershenson, D.M.; Miller, A.; Brady, W.E.; Paul, J.; Carty, K.; Rodgers, W.; Millan, D.; Coleman, R.L.; Moore, K.N.; Banerjee, S.; et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): An international, randomised, open-label, multicentre, phase 2/3 trial. Lancet 2022, 399, 541–553. [Google Scholar] [CrossRef]
- Holness, C.L.; Simmons, D.L. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993, 81, 1607–1613. [Google Scholar] [CrossRef] [PubMed]
- Chistiakov, D.A.; Killingsworth, M.C.; Myasoedova, V.A.; Orekhov, A.N.; Bobryshev, Y.V. CD68/macrosialin: Not just a histochemical marker. Lab. Investig. 2017, 97, 4–13. [Google Scholar] [CrossRef]
- Long, M.E.; Eddy, W.E.; Gong, K.Q.; Lovelace-Macon, L.L.; McMahan, R.S.; Charron, J.; Liles, W.C.; Manicone, A.M. MEK1/2 Inhibition Promotes Macrophage Reparative Properties. J. Immunol. 2017, 198, 862–872. [Google Scholar] [CrossRef] [PubMed]
- De, M.; Serpa, G.; Zuiker, E.; Hisert, K.B.; Liles, W.C.; Manicone, A.M.; Hemann, E.A.; Long, M.E. MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection. Front. Cell Infect. Microbiol. 2024, 14, 1275940. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jo, H.; Lee, E.-Y.; Cho, H.S.; Rayhan, M.A.; Cho, A.; Chae, C.-S.; You, H.J. THP-1 Monocytic Cells Are Polarized to More Antitumorigenic Macrophages by Serial Treatment with Phorbol-12-Myristate-13-Acetate and PD98059. Medicina 2024, 60, 1009. https://doi.org/10.3390/medicina60061009
Jo H, Lee E-Y, Cho HS, Rayhan MA, Cho A, Chae C-S, You HJ. THP-1 Monocytic Cells Are Polarized to More Antitumorigenic Macrophages by Serial Treatment with Phorbol-12-Myristate-13-Acetate and PD98059. Medicina. 2024; 60(6):1009. https://doi.org/10.3390/medicina60061009
Chicago/Turabian StyleJo, Hantae, Eun-Young Lee, Hyun Sang Cho, Md Abu Rayhan, Ahyoung Cho, Chang-Suk Chae, and Hye Jin You. 2024. "THP-1 Monocytic Cells Are Polarized to More Antitumorigenic Macrophages by Serial Treatment with Phorbol-12-Myristate-13-Acetate and PD98059" Medicina 60, no. 6: 1009. https://doi.org/10.3390/medicina60061009